American Kidney Fund Launches Phosphorus Management Education and Awareness Campaign
March 19, 2024 09:15 ET
|
American Kidney Fund
ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced a new patient-focused educational awareness campaign on managing high phosphorus, also known as...
American Kidney Fund Convenes Nation’s Kidney Community for 2024 Kidney Action Week™ March 18-22
March 18, 2024 09:47 ET
|
American Kidney Fund
ROCKVILLE, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) kicks off its fifth annual Kidney Action Week™, the nation’s only free online conference that draws patients,...
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Against Kidney Disease
March 15, 2024 08:59 ET
|
American Kidney Fund
ROCKVILLE, Md., March 15, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is pleased to announce its 2024 Class of Corporate Members who serve as strategic partners in AKF’s Corporate...
Unicycive Announces $50 Million Private Placement
March 14, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for...
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
March 13, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Promising Preclinical Results in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial Complete – LOS ALTOS, Calif., March 13, 2024 ...
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
March 07, 2024 16:12 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
March 04, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Kidney Month: 31 Day of Action to Equip and Empower People to Fight Kidney Disease
February 29, 2024 14:44 ET
|
American Kidney Fund
ROCKVILLE, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- The first day of March marks the beginning of Kidney Month, a month in which the American Kidney Fund (AKF) will mark 31 days of action that will...
Where You Live Impacts Your Ability to Save a Life Through Living Organ Donation, According to the 2024 American Kidney Fund Report Card
February 22, 2024 09:24 ET
|
American Kidney Fund
ROCKVILLE, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today released its fourth annual State of the States: Living Donor Protection Report Card with updates highlighting...
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
February 14, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...